1. HBW Insight

Taisho To Go Private To Aid 'Dynamic' Restructuring, R&D Investment

 
• By Lisa Takagi

The largest shareholder in major Japanese pharma firm Taisho, the founding Uehara family, intends to smooth the way to the restructuring and expansion of the business by acquiring and delisting all of its stock. The nearly $5bn size of the deal would makes it the biggest management buyout in Japanese corporate history.

Japan has had discussions for counter AMR measures for years.
• Source: Shutterstock

Taisho Pharmaceutical Holdings, which owns one of Japan’s largest pharmaceutical firms, over-the-counter focused Taisho Pharmaceutical Co., Ltd., initiated in late November what is set to be the largest management buyout (MBO) in the country’s corporate history, worth close to $5bn.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from HBW Insight